IOTA CARRAGEENAN COVID TRIAL

Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed. Marinomed has been able to show neutralizing activity towards the new coronavirus in vitro earlier this year.' said Dr. Our pivotal clinical data for Carragelose demonstrated alleviation of different coronavirus infections. 'With the world in the devastating grip of this SARS-CoV2 pandemic and nurses and doctors especially exposed, we are looking forward this very important clinical data from the Swansea trial.

The study population will be equally randomized into a treatment group (0.12 mg/ml iota-carrageenan / 0.4 mg/ml kappa-carrageenan in 0.5% saline) and a placebo group (0.5% saline) and will apply this study regime three times a day, one dose into each nostril and three throat sprays, over the course of eight weeks.

IOTA CARRAGEENAN COVID TRIAL

The design of the double-blind trial is finalized and planned to start shortly. The ongoing clinical trial is supported by Marinomed Biotech AG, the originator and licensor of Carragelose and Boots UK the Carragelose nasal spray used in the study is marketed as Boots Dual Defence in the United Kingdom. Further endpoints include infection with other respiratory viruses, usability of the spray for prophylaxis and the effects on quality adjusted life years (QALYs).

Objective of the study is to assess the efficacy of Carragelose nasal and throat spray in reducing the rate, severity, and duration of COVID-19 infections.

The investigator-initiated trial at Swansea will be recruiting 480 healthcare professionals managing COVID-19 patients during the pandemic. Vienna, Austria, Swansea UK, NovemMarinomed Biotech AG (VSE:MARI), a globally operating biopharmaceutical company, is pleased to announce today that the Swansea University Medical School plans a clinical trial with Iota-/kappa-carrageenan nasal spray as a COVID-19 Prophylaxis for Healthcare Professionals (ICE-COVID).

Iota carrageenan covid